Pre-association of polynuclear platinum anticancer agents on a protein, human serum albumin. Implications for drug design.
about
Factors affecting DNA-DNA interstrand cross-links in the antiparallel 3'-3' sense: a comparison with the 5'-5' directional isomer.Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity.Excursions in polynuclear platinum DNA binding.The trans influence in the modulation of platinum anticancer agent biology: the effect of nitrite leaving group on aquation, reactions with S-nucleophiles and DNA binding of dinuclear and trinuclear compounds.Understanding the interaction of an antitumoral platinum(II) 7-azaindolate complex with proteins and DNA.Effects of noncovalent platinum drug-protein interactions on drug efficacy: use of fluorescent conjugates as probes for drug metabolism.Solution studies of dinuclear polyamine-linked platinum-based antitumour complexes.Investigations of the binding of [Pt2(DTBPA)Cl2](II) and [Pt2(TPXA)Cl2](II) to DNA via various cross-linking modes.Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets.Studying the interactions of a platinum(II) 9-aminoacridine complex with proteins and oligonucleotides by ESI-TOF MS.Amide-based prodrugs of spermidine-bridged dinuclear platinum. Synthesis, DNA binding, and biological activity.Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural Factor
P2860
Q33608267-6274A50A-F9A7-4B85-A866-59F3BDE98607Q34377003-C42B70BA-9E8F-439F-BC2F-D07777466EB1Q34480028-FE45FE79-8C21-4EC4-9EB4-48FD3994F8A3Q34482184-5F3E6FF4-4200-4DDA-807C-DEB29A5E0574Q35222016-D8BE2D0E-8BB8-4857-BA50-8D16F94D2966Q35925653-BE7C9A1F-9452-4A05-BC45-829AC1ADF092Q35925656-8A89F644-7FB0-4E0E-9DC8-22A21EDDD4D1Q37291146-BE1FF134-2E3F-487B-AA16-858E6AE6A273Q38105454-5E703AC2-E2F1-4D8A-94B5-31442E2B05A5Q38465028-E24F4F7C-C376-4554-A887-BF1D192905AAQ39442095-411ECE27-58FE-49E5-BFBF-65D0BCB840C0Q40002791-318C4510-2CB3-4422-B910-1E10CAC28D7FQ58993871-0150D8F9-0176-498D-9997-6FB51CC8813E
P2860
Pre-association of polynuclear platinum anticancer agents on a protein, human serum albumin. Implications for drug design.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Pre-association of polynuclear ...... Implications for drug design.
@en
Pre-association of polynuclear ...... Implications for drug design.
@nl
type
label
Pre-association of polynuclear ...... Implications for drug design.
@en
Pre-association of polynuclear ...... Implications for drug design.
@nl
prefLabel
Pre-association of polynuclear ...... Implications for drug design.
@en
Pre-association of polynuclear ...... Implications for drug design.
@nl
P2093
P2860
P356
P1433
P1476
Pre-association of polynuclear ...... Implications for drug design.
@en
P2093
Brad T Benedetti
Eva I Montero
John B Mangrum
Michael J Oehlsen
Nicholas P Farrell
P2860
P304
P356
10.1039/B708433C
P407
P577
2007-10-02T00:00:00Z